EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of High‐Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric‐Coated Capsules in Healthy Chinese Subjects

Yifei Wang, Xiaojing Huang, Dandan Han, Liguang Duan, Qinchao Wang, Zihuan Zhang, Mingyue Liu, Linliu Du, Jianxin Wang

Clinical Pharmacology in Drug Development · 2026-06 · 15 (6)

DOI: 10.1002/cpdd.70069 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 04.06.2026. Verfasst von Yifei Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China. Hauptthemen laut MEDLINE: Lansoprazole, Food-Drug Interactions, Proton Pump Inhibitors, Diet, High-Fat. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effects of food on the pharmacokinetics (PKs) and safety of 30‐mg lansoprazole enteric‐coated capsules in healthy Chinese subjects were investigated from a bioequivalence trial. A randomized, open‐label, four‐period crossover study was conducted in 73 healthy subjects under both fasted and fed conditions. Serial blood samples were collected, and plasma lansoprazole concentrations were determined by liquid chromatography‐tandem mass spectrometry. PK parameters were calculated using a non‐compartmental model with Phoenix WinNonlin Version 8.3 software. The bioequivalence module of WinNonLin was used to statistically analyze the maximum plasma concentration (C max ), the area under the concentration–time curve from zero to the last measurable concentration (AUC 0‐t ), and the area under the concentration–time curve from zero to infinity (AUC 0‐∞ ) of lansoprazole in plasma. The results demonstrated bioequivalence between the test (T) and reference (R) formulations for all evaluated PK parameters. Compared with the fasted state, the C max , AUC 0‐t , and AUC 0‐∞ of lansoprazole significantly decreased by 60.67%, 46.39%, and 44.25%, respectively, following oral administration of lansoprazole 30 mg in the fed state. The incidence of adverse events (AEs) was similar between the fasted and fed states, with no serious AEs observed. Overall, food markedly reduced systemic exposure of 30 mg oral lansoprazole in Chinese subjects, indicating that food intake significantly affects its bioavailability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LansoprazoleFood-Drug InteractionsProton Pump InhibitorsDiet, High-FatHumansMaleCross-Over StudiesAdultYoung AdultFemaleArea Under CurveTherapeutic EquivalencyCapsulesTablets, Enteric-CoatedHealthy VolunteersAdministration, OralFastingTandem Mass SpectrometryChinaModels, BiologicalEast Asian People

Stichwörter der Autor:innen

food effecthigh‐fat meallansoprazolepharmacokineticssafety

Substanzen

LansoprazoleProton Pump InhibitorsCapsulesTablets, Enteric-Coated

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
  • School of Pharmacy, Hebei Medical University, Hebei Medical University, Shijiazhuang, P. R. China.

Zitieren

APA

Wang, Y., Huang, X., Han, D., Duan, L., Wang, Q., Zhang, Z., Liu, M., Du, L., & Wang, J. (2026). Effect of High‐Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric‐Coated Capsules in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 15(6). https://doi.org/10.1002/cpdd.70069

Vancouver

Wang Y, Huang X, Han D, Duan L, Wang Q, Zhang Z, et al. Effect of High‐Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric‐Coated Capsules in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2026;15(6). doi:10.1002/cpdd.70069

BibTeX
@article{Wang2026,
  author = {Wang, Yifei and Huang, Xiaojing and Han, Dandan and Duan, Liguang and Wang, Qinchao and Zhang, Zihuan and Liu, Mingyue and Du, Linliu and Wang, Jianxin},
  title = {Effect of High‐Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric‐Coated Capsules in Healthy Chinese Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cpdd.70069}
}
Kostenlos starten →